JK-1201I in Triple Negative Breast Cancer Patients with Brain Metastases
Status:
NOT_YET_RECRUITING
Trial end date:
2026-10-26
Target enrollment:
Participant gender:
Summary
This study was designed to evaluate the safety, efficacy and pharmacokinetics of JK-1201I in triple negative breast cancer patients with brain metastases.